SEQUENTIAL OCCURRENCE OF IGM, IGM IGG, AND GP120-IGM/IGG COMPLEMENT COMPLEXES ON CD4(+) LYMPHOCYTES IN RELATION TO CD4(+) BLOOD LYMPHOCYTE DEPLETION IN HIV+ HEMOPHILIA PATIENTS - RESULTS OF A 10-YEAR STUDY/
V. Daniel et al., SEQUENTIAL OCCURRENCE OF IGM, IGM IGG, AND GP120-IGM/IGG COMPLEMENT COMPLEXES ON CD4(+) LYMPHOCYTES IN RELATION TO CD4(+) BLOOD LYMPHOCYTE DEPLETION IN HIV+ HEMOPHILIA PATIENTS - RESULTS OF A 10-YEAR STUDY/, Immunology letters, 47(1-2), 1995, pp. 97-102
The concept of autoimmune mechanisms playing an integral role in the p
athogenesis of HIV disease is rapidly gaining ground. In this study, w
e determined IgM and IgG antibodies, complement fragments and gp120 on
the surface of CD4(+) lymphocytes using double-fluorescence flow cyto
metry. Sequential analysis demonstrated an inverse relationship of aut
oantibodies and CD4(+) lymphocyte counts in the peripheral blood. HIV patients without autoantibodies (16/104 = 15%) had the highest CD4(+)
blood cell counts (324 +/- 264/mu l; mean +/- SD). CD4(+) counts were
successively lower in patients with complement-fixing IgM (243 +/- 24
0/mu l), complement-fixing IgG and IgM (139 +/- 138/mu l), or gp120-Ig
M/IgG complement complexes on the surface of CD4(+) cells (38 +/- 45/m
u l, P = 0.03). Individual patient profiles show that IgM autoantibodi
es typically are formed early after HIV infection and appear to deplet
e CD4(+) lymphocytes very slowly, whereas complement-fixing IgG autoan
tibodies are generated at a later stage and deplete CD4(+) lymphocytes
more efficiently. The presence of both soluble gp120 and complement-f
ixing autoantibodies on CD4(+) lymphocytes is associated with very low
CD4(+) cell counts and coincides with progression to terminal disease
. Early during HIV infection autoantibody production is rather unstabl
e, but it becomes more stable with disease progression and persists in
advanced stages of the disease. These data suggest that autoantibody
formation against CD4(+) lymphocytes is a pathogenic mechanism for CD4
(+) cell depletion.